博雅生物: 公司关于2025年半年度利润分配预案的公告

Core Viewpoint - The company has announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 1.50 yuan per 10 shares, with no bonus shares or capital increase [1][4][5]. Summary by Sections Profit Distribution Plan - The profit distribution plan includes a cash dividend of 80,679,798.08 yuan, with total distributable profits amounting to 2,886,930,513.07 yuan, based on the parent company's financial statements [2][3]. - The total distributable profit as of June 30, 2025, is 2,810,078,733.67 yuan, considering the lower of the profits available for distribution from the consolidated and parent company financial statements [2][3]. Approval Process - The audit committee and the board of directors have reviewed and approved the profit distribution plan, which will be submitted for approval at the company's first extraordinary general meeting of 2025 [1][2][4]. Compliance and Justification - The profit distribution plan complies with relevant regulations, including the Company Law and the guidelines for cash dividends, ensuring it aligns with the company's long-term return strategy for shareholders [4][5]. - The plan reflects the company's operational performance and future funding needs while ensuring reasonable returns for shareholders [4][5]. Industry Context - The blood products sector is characterized by high demand and stringent regulatory oversight, making licenses for blood product companies scarce. This has led to a favorable market environment for existing players [5]. - The pharmaceutical industry in China is experiencing rapid growth, driven by economic development and healthcare reforms, presenting significant opportunities for companies in this sector [5].